Want to join the conversation?
$COL still expects FY16 total sales of $5.3-5.4Bil and EPS of $5.45-5.65. Total segment operating margins is still expected to be about 21% and cash flow from operations is projected to be $750-850MM. $COL still sees total research and development investment of about $1Bil, income tax rate of 22-23% and capital expenditures of about $200MM.
Biodefense therapeutics firm $PIP announced an all-stock merger with biotech Altimmune. The respective boards of the two companies unanimously approved the merger.
$YHOO is reporting today after market close. Nobody cares about this stock.